Beam Therapeutics Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Los beneficios de Beam Therapeutics han disminuido a una tasa media anual de -17.8%, mientras que en la industria Biotechs los beneficios crecieron en un 12.7% anualmente. Los ingresos han ido creciendo a una tasa media de 80.9% al año.
Información clave
-17.8%
Tasa de crecimiento de los beneficios
51.6%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | 80.9% |
| Rentabilidad financiera | -13.5% |
| Margen neto | -35.1% |
| Última actualización de beneficios | 31 Dec 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Beam Therapeutics: A 'Hold' Amid High Valuation And Uncertain Revenue Prospects
Apr 24Lacklustre Performance Is Driving Beam Therapeutics Inc.'s (NASDAQ:BEAM) Low P/S
Apr 07
Beam Therapeutics Inc. (NASDAQ:BEAM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 01Things Look Grim For Beam Therapeutics Inc. (NASDAQ:BEAM) After Today's Downgrade
Feb 29Beam Therapeutics: Cool Tech, But At A Way Inflated Price For Now
Feb 08This Just In: Analysts Are Boosting Their Beam Therapeutics Inc. (NASDAQ:BEAM) Outlook for This Year
Nov 01We're Hopeful That Beam Therapeutics (NASDAQ:BEAM) Will Use Its Cash Wisely
Jul 23Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation
Apr 08Industry Analysts Just Made A Massive Upgrade To Their Beam Therapeutics Inc. (NASDAQ:BEAM) Revenue Forecasts
Nov 08Beam Therapeutics: Now Is Not The Right Time To Own
Sep 15Beam Therapeutics GAAP EPS of -$1.02 misses by $0.05, revenue of $16.65M beats by $7.21M
Aug 09Beam drops 19% as FDA issues clinical hold on blood cancer candidate
Aug 01Revisiting Beam Therapeutics Among Collaborative Catalysts
Jul 10Newsflash: Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Have Been Trimming Their Revenue Forecasts
May 10Beam Therapeutics Worth Watching Because Of Pfizer Interest?
Apr 21Beam Therapeutics: Getting More And More Interesting
Apr 10Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Mar 03Some Beam Therapeutics Inc. (NASDAQ:BEAM) Analysts Just Made A Major Cut To Next Year's Estimates
Mar 02Pfizer's Partnership With Beam Therapeutics About Becoming Global Leader In mRNA/Gene Therapy
Jan 19Beam Therapeutics: An Early Company In A Promising Field
Dec 27Beam Therapeutics: Recent Selling Pressure Leaves Behind A CRISPR Buying Opportunity
Dec 20Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio
Oct 01Beam Therapeutics: If You Buy Into The Technology, Buy Into The Stock
Aug 25Desglose de ingresos y gastosBeta
Cómo gana y gasta dinero Beam Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 31 Dec 23 | 378 | -133 | 117 | 0 |
| 30 Sep 23 | 82 | -285 | 96 | 0 |
| 30 Jun 23 | 80 | -298 | 93 | 0 |
| 31 Mar 23 | 77 | -287 | 92 | 31 |
| 31 Dec 22 | 61 | -289 | 88 | 0 |
| 30 Sep 22 | 92 | -315 | 83 | 0 |
| 30 Jun 22 | 77 | -234 | 77 | 0 |
| 31 Mar 22 | 60 | -238 | 66 | 54 |
| 31 Dec 21 | 52 | -371 | 57 | 0 |
| 30 Sep 21 | 1 | -401 | 48 | -6 |
| 30 Jun 21 | 0 | -408 | 40 | 0 |
| 31 Mar 21 | 0 | -366 | 33 | 0 |
| 31 Dec 20 | 0 | -196 | 30 | 0 |
| 30 Sep 20 | 0 | -132 | 27 | 7 |
| 30 Jun 20 | 0 | -119 | 25 | 2 |
| 31 Mar 20 | 0 | -106 | 23 | 4 |
| 31 Dec 19 | 0 | -91 | 21 | 0 |
| 30 Sep 19 | 0 | -86 | 18 | 8 |
| 30 Jun 19 | 0 | -134 | 15 | 7 |
| 31 Mar 19 | 0 | -124 | 13 | 6 |
| 31 Dec 18 | 0 | -117 | 12 | 6 |
Ingresos de calidad: BEAM actualmente no es rentable.
Margen de beneficios creciente: BEAM actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: BEAM no es rentable, y las pérdidas han aumentado en los últimos 5 años a un ritmo de 17.8% al año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de BEAM en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: BEAM no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-8.9%).
Rentabilidad financiera
Alta ROE: BEAM tiene una rentabilidad financiera negativa (-13.5%), ya que actualmente no es rentable.